Colistin is a last-resort agent for the treatment of infections due to Gram-negative bacteria with difficult-to-treat resistance. The primary objective of this post hoc analysis of a cross-sectional study conducted in 22 Italian hospitals was to assess factors associated with inadequate intravenous colistin dosage. Overall, 187 patients receiving intravenous colistin were included in the analyses. Inadequate colistin dosages were administered in 27% of cases (50/187). In multivariable analysis, AKI (dummy variable with KDIGO stage 0 as a reference, odds ratio (OR) 3.98 with 95% confidence interval (CI) 1.48–10.74 for stage 1, OR 4.44 with 95% CI 1.17–16.93 for stage 2, OR 9.41 with 95% CI 1.59–55.70 for stage 3; overall p = 0.001) retained an independent association with inadequate colistin dosage, whereas the presence of a central venous catheter was associated with adequate colistin dosage (OR: 0.34 for inadequate dosage, 95% CI: 0.16–0.72, p = 0.004). These results were confirmed in an additional multivariable model with the center as a random effect. The association between AKI and inadequate dosage may reflect the perception of an increased risk of nephrotoxicity in patients with impaired renal function, which nonetheless should not be accompanied by dosage reductions beyond those recommended and could represent the target of dedicated antimicrobial stewardship efforts.

Factors associated with inadequate intravenous colistin dosages: Post hoc analysis of a multicenter, cross-sectional study / Giacobbe D.R.; Mirabella M.; Rinaldi M.; Losito A.R.; Raffaelli F.; Del Puente F.; Saffioti C.; Mikulska M.; Giannella M.; Viale P.; Tumbarello M.; Bassetti M.. - In: ANTIBIOTICS. - ISSN 2079-6382. - ELETTRONICO. - 10:12(2021), pp. 1554.1554-1554.10121554. [10.3390/antibiotics10121554]

Factors associated with inadequate intravenous colistin dosages: Post hoc analysis of a multicenter, cross-sectional study

Rinaldi M.;Giannella M.;Viale P.;
2021

Abstract

Colistin is a last-resort agent for the treatment of infections due to Gram-negative bacteria with difficult-to-treat resistance. The primary objective of this post hoc analysis of a cross-sectional study conducted in 22 Italian hospitals was to assess factors associated with inadequate intravenous colistin dosage. Overall, 187 patients receiving intravenous colistin were included in the analyses. Inadequate colistin dosages were administered in 27% of cases (50/187). In multivariable analysis, AKI (dummy variable with KDIGO stage 0 as a reference, odds ratio (OR) 3.98 with 95% confidence interval (CI) 1.48–10.74 for stage 1, OR 4.44 with 95% CI 1.17–16.93 for stage 2, OR 9.41 with 95% CI 1.59–55.70 for stage 3; overall p = 0.001) retained an independent association with inadequate colistin dosage, whereas the presence of a central venous catheter was associated with adequate colistin dosage (OR: 0.34 for inadequate dosage, 95% CI: 0.16–0.72, p = 0.004). These results were confirmed in an additional multivariable model with the center as a random effect. The association between AKI and inadequate dosage may reflect the perception of an increased risk of nephrotoxicity in patients with impaired renal function, which nonetheless should not be accompanied by dosage reductions beyond those recommended and could represent the target of dedicated antimicrobial stewardship efforts.
2021
Factors associated with inadequate intravenous colistin dosages: Post hoc analysis of a multicenter, cross-sectional study / Giacobbe D.R.; Mirabella M.; Rinaldi M.; Losito A.R.; Raffaelli F.; Del Puente F.; Saffioti C.; Mikulska M.; Giannella M.; Viale P.; Tumbarello M.; Bassetti M.. - In: ANTIBIOTICS. - ISSN 2079-6382. - ELETTRONICO. - 10:12(2021), pp. 1554.1554-1554.10121554. [10.3390/antibiotics10121554]
Giacobbe D.R.; Mirabella M.; Rinaldi M.; Losito A.R.; Raffaelli F.; Del Puente F.; Saffioti C.; Mikulska M.; Giannella M.; Viale P.; Tumbarello M.; Bassetti M.
File in questo prodotto:
File Dimensione Formato  
antibiotics-10-01554.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 410.26 kB
Formato Adobe PDF
410.26 kB Adobe PDF Visualizza/Apri
antibiotics-10-01554-s001.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per accesso libero gratuito
Dimensione 86.69 kB
Formato Zip File
86.69 kB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/861834
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact